BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 10770186)

  • 1. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
    Shimatsu A; Nakamura A; Takahashi Y; Fujio S; Satoh F; Tahara S; Nishioka H; Takano K; Yamashita M; Arima H; Tominaga A; Tateishi S; Matsushita Y
    Endocr J; 2021 Jul; 68(7):791-805. PubMed ID: 33692246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF; Liang D; Zhong LY
    Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
    Rabbiosi S; Peroni E; Tronconi GM; Chiumello G; Losa M; Weber G
    Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P; Díez JJ
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA; Bernstein R; Chynn KY; Kourides IA
    J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
    Lucas T; Astorga R; Catalá M;
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
    Mannavola D; Persani L; Vannucchi G; Zanardelli M; Fugazzola L; Verga U; Facchetti M; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):176-81. PubMed ID: 15670193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thyrotropin-secreting pituitary adenomas].
    Caron P
    Presse Med; 2009 Jan; 38(1):107-11. PubMed ID: 18980829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macro- and microadenoma of thyrotropin secreting pituitary tumors--two clinical cases.
    Hubalewska-Hola A; Fröss K; Kostecka-Matyja M; Sowa-Staszczak A; Szybiński Z; Huszno B; Ptak M
    Przegl Lek; 2003; 60(11):768-71. PubMed ID: 15058054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.